Abstracts tagged "Pediatric rheumatology"

Abstract Number: 001 • 2023 Pediatric Rheumatology Symposium
Serious Infections Among Children with Systemic Lupus Erythematosus in the Pediatric Health Information System
Jordan Roberts, Anna Faino, Mersine Bryan, Jonathan Cogen and Esi Morgan, Seattle Children's Hospital, Seattle, WA
Background/Purpose: High rates of serious infection have beenreported in pediatric systemic lupus erythematosus (pSLE), but modern care practices including pneumococcal vaccination, changing corticosteroid use, and…
Abstract Number: 044 • 2023 Pediatric Rheumatology Symposium
Validation of Newly Proposed Classification Criteria for Pediatric Chronic Nonbacterial Osteomyelitis: A Virginia Cohort
Kelley Lee¹, Ashley Kim² and Aarat Patel³, ¹University of Richmond, Richmond, VA, ²University of Virginia, Charlottesville, VA, ³Bon Secours Mercy Health / University of Virginia, GLEN ALLEN, VA
Background/Purpose: Chronic nonbacterial osteomyelitis (CNO) is an aseptic autoinflammatory bone disease of unknown etiology. This diagnosis can be delayed due to the non-specific nature of…
Abstract Number: 072 • 2023 Pediatric Rheumatology Symposium
Musculoskeletal Ultrasound Findings in Children with Psoriasis
Laura Nedorezov, Tracy Ting and Patricia Vega-Fernandez, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: The presentation of juvenile psoriatic arthritis (JPsA) in children with psoriasis can be insidious and poses a diagnostic challenge. Musculoskeletal ultrasound (MSUS) has emerged…
Abstract Number: 115 • 2023 Pediatric Rheumatology Symposium
Development of an Electronic Clinical Phenotype to Identify Potential Study Subjects with Juvenile Arthritis
Alysha Taxter¹, Marc Natter², Min-Lee Chang², Laura Schanberg³, Valarie Morrow⁴, Eveline Wu⁵, Tedryl Bumpass⁴, Alex Fist⁴, Meg Waite⁶, Vincent Del Gaizo⁷, Melanie Kohlheim⁷ and CARRA Registry Investigators⁷, ¹Nationwide Children's Hospital, Columbus, OH, ²Boston Children's Hospital, Boston, MA, ³Duke University Medical Center, Durham, NC, ⁴Duke University, Durham, NC, ⁵UNC Chapel Hill, Chapel Hill, NC, ⁶Boston Children's Hospital, Boston, MA, ⁷CARRA, Washington, DC
Background/Purpose: The LIMIT-JIA trial is the first study of the use of biologic therapy to prevent disease extension in children with newly diagnosed, uncomplicated, oligo-articular…
Abstract Number: 004 • 2023 Pediatric Rheumatology Symposium
Analysis of Patients with Juvenile Dermatomyositis Compared to Healthy Controls Using CITE-seq Identifies Differences in Cell Composition and Gene and Epitope Expression
Camilla Wibrand¹, Emily Flynn², Gabrielle Rabadam², George Hartoularos², Yang Sun², Chun Ye², Susan Kim³, Marina Sirota² and Jessica Neely¹, ¹UCSF, San Francisco, CA, ²University of California, San Francisco, San Francisco, CA, ³UCSF Benioff Children's Hospital, San Francisco, CA
Background/Purpose: Juvenile dermatomyositis (JDM) is a rare and serious systemic autoimmune condition, and much remains unknown about the pathogenesis, the immune cell types and cell-specific…
Abstract Number: 045 • 2023 Pediatric Rheumatology Symposium
Patient Reported Outcomes in Pediatric Vasculitis
Clare Peckenpaugh¹, Aimee Hersh², CJ Inman¹, Sara Stern¹, Erin Treemarcki², Peter Merkel³ and Karen James¹, ¹University of Utah Department of Pediatrics, Salt Lake City, UT, ²University of Utah, Salt Lake City, UT, ³University of Pennsylvania, Philidelphia, PA
Background/Purpose: Vasculitis is a group of multisystem, often relapsing diseases that can affect patients through disease activity, damage, and treatment toxicity. Vasculitis in adults often…
Abstract Number: 074 • 2023 Pediatric Rheumatology Symposium
Clinical Characteristics of Juvenile Systemic Sclerosis in Korea: A 30-year Single Center Study
Jieun Jeong¹, Minji Kim¹, Jiwon Jung², Seon Hee Lim³ and Seong Heon Kim¹, ¹Department of Pediatrics, Seoul National University Children’s Hospital, Seoul, Republic of Korea, ²Department of Pediatrics, Asan Medical Center Children’s Hospital, University of Ulsan College of Medicine, Seoul, Republic of Korea, ³Department of Pediatrics, Pusan National University Children’s Hospital, Yangsan, Republic of Korea
Background/Purpose: Juvenile systemic sclerosis (jSSc) is a rare autoimmune, chronic, multisystem, connective tissue disease characterized by progressive tissue fibrosis of the skin and internal organs.…
Abstract Number: 121 • 2023 Pediatric Rheumatology Symposium
The Effectiveness of Tonsillectomy in Periodic Fever, Aphthous Ulcer, Pharyngitis, and Adenitis Syndrome in Pediatric Patients
John Storwick¹ and Marinka Twilt², ¹Alberta Children's Hospital/University of Calgary, Calgary, AB, Canada, ²Alberta Children's Hospital, Calgary, AB, Canada
Background/Purpose: Periodic Fevers with Aphthous Ulcers, Pharyngitis, and Adenitis Syndrome (PFAPA Syndrome) is the most common pediatric periodic fever syndrome. The most recent diagnostic criteria…
Abstract Number: 0370 • ACR Convergence 2022
Preliminary Findings from a Randomized Clinical Trial Show a Remotely Delivered Psychological Intervention May Be Beneficial to Youth with Childhood-Onset Lupus
Natoshia Cunningham¹, Samantha Ely¹, ashley Danguecan², Mallet Reid³, Alaina Miller⁴, Mathew Reeves³, Lawrence Ng², Paris Moaf², Sarah Mossad², Tala El Tal⁵, Luana Flores Pereira², Deborah Levy⁶, Linda Hiraki⁷, Jennifer Stinson², Sara Ahola Kohut², khalid abulaban⁸, Elizabeth Kessler⁹, Stacy Allen⁸, Tamar Rubinstein¹⁰, Evin Rothschild¹¹, Natalie Rosenwasser¹², Kabita Nanda¹², Susan Canny¹², Emily Smitherman¹³, Livie Huie¹³, James Birmingham¹⁴, Allison Thompson¹⁵, Janel Thompson¹⁵, Miranda Moyer¹⁵, Angela Chapson Emily Nguyen¹⁵ and Andrea Knight⁵, ¹Michigan State University, Grand Rapids, MI, ²The Hospital for Sick Children, Toronto, ON, Canada, ³Michigan State University, East Lansing, MI, ⁴Wright State University, Dayton, OH, ⁵The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ⁶Division of Rheumatology, The Hospital for Sick Children; Child Health Evaluative Services, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ⁷The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, Genetics and Genome Biology, SickKids Research Institute, Toronto, ON, Canada, ⁸Spectrum Health, Grand Rapids, MI, ⁹Spectrum Health Helen DeVos Children's Hospital, Michigan State University, Grand Rapids, MI, ¹⁰Albert Einstein College of Medicine, White Plains, NY, ¹¹Children's Hospital at Montefiore, Bronx, NY, ¹²Seattle Children's Hospital, Seattle, WA, ¹³University of Alabama at Birmingham, Birmingham, AL, ¹⁴Metro Health, Grand Rapids, MI, ¹⁵Patient/Caregiver Co-Investigative Team, Grand Rapids, MI
Background/Purpose: Childhood-onset systemic lupus erythematosus (cSLE) is often associated with symptoms such as fatigue, pain, and depressive symptoms that contribute to poor health-related quality of…
Abstract Number: 0860 • ACR Convergence 2022
Characteristics of Transitioning JIA Patients: Who Is Arriving on the Adult Rheumatologists’ Doorsteps?
Teresa Semalulu¹, KAREN BEATTIE¹, Roberta Berard², Jaime Guzman³ and Michelle Batthish¹, ¹McMaster University, Hamilton, ON, Canada, ²London Health Sciences Centre, London, ON, Canada, ³University of British Columbia and BC Children's Hospital, Vancouver, BC, Canada
Background/Purpose: Patients with JIA are at an increased risk of loss to follow-up, morbidity and mortality as they transition from pediatric to adult care. Thus,…
Abstract Number: 1242 • ACR Convergence 2022
Validation of a Novel Ultrasound Scoring System for the Evaluation of Pediatric Knee Arthritis
Patricia Vega-Fernandez¹, Theresa Hennard¹, Kelly Rogers¹, Mekibib Altaye², Sherry Thornton², Alyssa Sproles², Amy Cassedy³, Arthur Meyers¹ and Tracy Ting¹, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Cincinnati Children's Hospital, Cincinnati, OH, ³Cincinnati Children's hospital medical center, Cleveland, OH
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is the most common chronic rheumatic disease in children. Currently, clinical evaluation of arthritis is subjective and provider dependent. Musculoskeletal…
Abstract Number: 1368 • ACR Convergence 2022
How Common Is the Coexistence of Juvenile Localized and Systemic Scleroderma? Results of a Multination Survey
Ivan Foeldvari¹, Nicola Helmus² and Suzanne Li³, ¹Hamburger Zentrum für Kinder- und Jugendrheumatologie, Hamburg, Germany, ²Hamburg Centre for Pediatric and Adolescence Rheumatology, Hamburg, Germany, ³Hackensack Meridian School of Medicine, Joseph M. Sanzari Children's Hospital, West Orange, NJ
Background/Purpose: Pediatric scleroderma consists of two diseases, juvenile localized scleroderma (jLS) and juvenile systemic sclerosis (jSSc). While jLS and jSSc share some disease processes, there…
Abstract Number: 1868 • ACR Convergence 2022
B Cell Count in Juvenile Dermatomyositis: A Biomarker of Disease
Christopher Costin¹, Gabrielle Morgan², Amer Khojah³ and Lauren Pachman⁴, ¹Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ²Ann & Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine, Chicago, IL, ³Umm Al-Qura University, Makkah, Saudi Arabia, ⁴Northwestern's Feinberg School of Medicine. Ann and Robert H. Lurie Children's Hospital of Chicago; Stanley Manne Children's Research Institute of Chicago, Lake Forest, IL
Background/Purpose: Juvenile Dermatomyositis(JDM) is heterogenous disease with many presentations. The underlying immune pathophysiology of JDM remains complex with varying phenotypes. B Cells remain a critical…
Abstract Number: 1944 • ACR Convergence 2022
Description and Delays in Care in the Bridge to Adult Care from Childhood for Young Adults with Rheumatic Disease (BACC YARD) Program, a Pediatric-to-Adult Rheumatology Transition Program
John Bridges¹, Livie Huie², Amanda Alexander³, Randy Cron², Maria Danila², Victoria Gennaro⁴, Laura Hughes², Bailey Lipham⁵, Linda McAllister⁶, Matthew Mullen⁷, Annelle Reed⁴, Daniel Reiff², Carolyn Smith⁴, Emily Smitherman², Matthew Stoll², Peter Weiser² and Melissa Mannion², ¹University of Alabama at Birmingham/Children's of Alabama, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³University of Alabama at Birmingham, Homewood, AL, ⁴Children's of Alabama, Birmingham, AL, ⁵University of Alabama Medical School, Birmingham, AL, ⁶Children's of Alabama, Trussville, AL, ⁷University of Alabama-Birmingham, Vestavia Hills, AL
Background/Purpose: Children with chronic rheumatic conditions age and require transfer to adult rheumatologists for continued care. The transition period from pediatric to adult-oriented care is…
Abstract Number: 0512 • ACR Convergence 2022
Development of CARRA Biologic Consensus Treatment Plans for Management of Refractory Moderate Juvenile Dermatomyositis
Matthew Sherman¹, Hanna Kim² and Stacey Tarvin³, ¹Muscle Disease Unit, Laboratory of Muscle Stem Cells and Gene Regulation, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH); Children’s National Hospital, Washington, DC, ²Division of Rheumatology, Department of Medicine, George Washington University School of Medicine and Health Sciences; Juvenile Myositis Therapeutic and Translation Studies Unit, PTRB, NIAMS, NIH, Bethesda, MD, ³Riley Hospital for Children at Indiana University Health, Indianapolis, IN
Background/Purpose: There is a paucity of prospective clinical trials evaluating treatments for juvenile dermatomyositis (JDM). Consensus treatment plans (CTPs) are designed to facilitate comparative effectiveness…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.